Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11992MR)

This product GTTS-WQ11992MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11992MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ68MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ11226MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ170MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ12018MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ8482MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ4566MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ3767MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ5155MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW